MINNEAPOLIS, May 22, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and Regulus Therapeutics Inc., a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced continued technical and clinical collaboration following release of Regulus' positive topline results from the second cohort of patients in its Phase 1b MAD (multiple ascending dose) study of RGLS8429 for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADP ...

HOLMDEL, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (Nasdaq: BKYI), an innovative provider of workforce and customer Identity and Access Management (IAM) solutions featuring passwordless, phoneless and token-less Identity-Bound Biometric (IBB) authentication, today announced that it currently expects to file its audited 2023 results with the SEC on Form 10-K next week. BIO-key also expects to report its Q1 2024 results and hold an investor call by the end of next week. The Company w ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-07928 Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject ...

Bio-Rad Laboratories, Inc. (BIO) posted first-quarter 2024 adjusted earnings per share (EPS) of $2.29, beating the Zacks Consensus Estimate by 12.3%. However, the bottom line declined 31.4% from the prior-year quarter’s levels.The quarter’s adjustments eliminate the impacts of certain non-recurring items like the amortization of purchased intangibles, Restructuring costs, gains/losses from the change in the fair market value of equity securities and gains/losses on equity-method investments.The company’s GA ...

Bio-Rad Laboratories, Inc. (NYSE:BIO) Q1 2024 Earnings Conference Call May 7, 2024 5:00 PM ET Company Participants Edward Chung - Head, Investor Relations Norman Schwartz - Chief Executive Officer Andy Last - Executive Vice President and COO Roop Lakkaraju - CFO Conference Call Participants Patrick Donnelly - Citi Selena Lu - UBS Jack Meehan - Nephron Research Conor McNamara - RBC Capital Markets Operator Good afternoon everyone, and welcome to today's Bio-Rad First Quarter 2024 Earnings Results Conference ...

Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.29 per share, beating the Zacks Consensus Estimate of $2.04 per share. This compares to earnings of $3.34 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 12.25%. A quarter ago, it was expected that this maker of instruments used in biomedical research would post earnings of $2.93 per share when it actually produced earnings of $3.10, delivering a surprise of 5.8 ...

The market expects Bio-Rad Laboratories (BIO) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended March 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be rel ...

Bio-Rad Laboratories, Inc. (BIO) is expected to release first-quarter 2024 results on May 2 after the closing bell.The company posted adjusted earnings per share (EPS) of $3.10 in the last reported quarter, beating the Zacks Consensus Estimate by 5.8%. Bio-Rad beat earnings estimates in three of the trailing four quarters and missed the same in one, the average surprise being 1.93%.Let’s look at how things have shaped up before this announcementFactors at PlayLife ScienceWithin the Life Science business, th ...

Bio-Rad (BIO) has been facing the impact of funding issues in the biopharmaceutical or BioPharma space, macroeconomic headwinds and competitive pressure. The stock carries a Zacks Rank #4 (Sell) currently.Since the beginning of 2023, Bio-Rad has been witnessing softness in smaller BioPharma companies, where historically, demand for life science products has been strong. This directly correlates with the funding constraints the broader pharmaceutical industry has started to experience. Management stated that ...

- Bio-Rad expects to make equity investment in support of deal - Agreement provides for global exclusivity in transplant monitoring commercialization - Bio-Rad granted subsequent investment option upon FDA clearance IRVINE, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced a partnership agreement with Bio-Rad Laboratories (NYSE:BIO), a global leader in life science research and clinical diagnostics products, for the commercializati ...